Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GLSI NASDAQ:LPTX NASDAQ:LXEO NASDAQ:ZURA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGLSIGreenwich LifeSciences$24.14+3.1%$24.86$7.78▼$34.10$354.38M1.4261,808 shs56,149 shsLPTXLeap Therapeutics$2.05$0.00▼$0.00$84.95M-0.0640.67 million shs760.56 million shsLXEOLexeo Therapeutics$4.59-1.3%$5.50$3.60▼$10.99$359.23M1.39923,083 shs226,919 shsZURAZura Bio$3.58-2.9%$4.76$1.00▼$7.44$339.20M0.03703,365 shs197,893 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGLSIGreenwich LifeSciences-2.70%+8.13%-13.97%-22.10%+154.46%LPTXLeap Therapeutics0.00%0.00%0.00%0.00%+204,999,900.00%LXEOLexeo Therapeutics+6.41%+10.45%-8.64%-27.12%+18.02%ZURAZura Bio-0.54%+4.25%-22.03%-42.86%+206.67%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGLSIGreenwich LifeSciences$24.14+3.1%$24.86$7.78▼$34.10$354.38M1.4261,808 shs56,149 shsLPTXLeap Therapeutics$2.05$0.00▼$0.00$84.95M-0.0640.67 million shs760.56 million shsLXEOLexeo Therapeutics$4.59-1.3%$5.50$3.60▼$10.99$359.23M1.39923,083 shs226,919 shsZURAZura Bio$3.58-2.9%$4.76$1.00▼$7.44$339.20M0.03703,365 shs197,893 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGLSIGreenwich LifeSciences-2.70%+8.13%-13.97%-22.10%+154.46%LPTXLeap Therapeutics0.00%0.00%0.00%0.00%+204,999,900.00%LXEOLexeo Therapeutics+6.41%+10.45%-8.64%-27.12%+18.02%ZURAZura Bio-0.54%+4.25%-22.03%-42.86%+206.67%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGLSIGreenwich LifeSciences 2.33Hold$47.5096.77% UpsideLPTXLeap Therapeutics 1.00SellN/AN/ALXEOLexeo Therapeutics 2.88Moderate Buy$20.14338.84% UpsideZURAZura Bio 2.67Moderate Buy$10.75200.70% UpsideCurrent Analyst Ratings BreakdownLatest LPTX, ZURA, GLSI, and LXEO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026LXEOLexeo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/29/2026LXEOLexeo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/15/2026GLSIGreenwich LifeSciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/15/2026LXEOLexeo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/11/2026LXEOLexeo Therapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.005/1/2026LXEOLexeo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/17/2026LXEOLexeo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/8/2026ZURAZura Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/23/2026ZURAZura Bio Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $11.003/20/2026ZURAZura Bio OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$16.00 ➝ $15.00(Data available from 6/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGLSIGreenwich LifeSciencesN/AN/AN/AN/A$0.03 per shareN/ALPTXLeap TherapeuticsN/AN/AN/AN/A$0.91 per shareN/ALXEOLexeo TherapeuticsN/AN/AN/AN/A$3.38 per shareN/AZURAZura BioN/AN/AN/AN/A$1.38 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGLSIGreenwich LifeSciences-$19.36M-$1.57N/AN/AN/AN/A-941.15%-368.53%8/13/2026 (Estimated)LPTXLeap Therapeutics-$67.56M-$1.22N/AN/AN/AN/A-247.44%-146.51%N/ALXEOLexeo Therapeutics-$99.96M-$1.45N/AN/AN/AN/A-47.48%-41.72%8/13/2026 (Estimated)ZURAZura Bio-$99.35M-$1.09N/AN/AN/AN/A-55.74%-48.07%8/13/2026 (Estimated)Latest LPTX, ZURA, GLSI, and LXEO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026LXEOLexeo Therapeutics-$0.29-$0.25+$0.04-$0.25N/AN/A5/7/2026Q1 2026ZURAZura Bio-$0.17-$0.22-$0.05-$0.22N/AN/A3/30/2026Q4 2025LXEOLexeo Therapeutics-$0.32-$0.27+$0.05-$0.27N/AN/A3/16/2026Q4 2025ZURAZura Bio-$0.18-$0.49-$0.31-$0.49N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGLSIGreenwich LifeSciencesN/AN/AN/AN/AN/ALPTXLeap TherapeuticsN/AN/AN/AN/AN/ALXEOLexeo TherapeuticsN/AN/AN/AN/AN/AZURAZura BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGLSIGreenwich LifeSciencesN/A2.012.01LPTXLeap TherapeuticsN/A1.341.34LXEOLexeo TherapeuticsN/A14.1614.16ZURAZura BioN/A19.3319.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGLSIGreenwich LifeSciences4.16%LPTXLeap Therapeutics30.46%LXEOLexeo Therapeutics60.67%ZURAZura Bio61.14%Insider OwnershipCompanyInsider OwnershipGLSIGreenwich LifeSciences51.47%LPTXLeap Therapeutics4.30%LXEOLexeo Therapeutics2.00%ZURAZura Bio12.37%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGLSIGreenwich LifeSciences314.68 million7.12 millionNot OptionableLPTXLeap Therapeutics4041.44 million39.66 millionN/ALXEOLexeo Therapeutics5878.52 million76.95 millionNot OptionableZURAZura Bio394.88 million83.14 millionOptionableLPTX, ZURA, GLSI, and LXEO HeadlinesRecent News About These CompaniesZura Bio (ZURA) Gets a Buy from OppenheimerJune 13 at 7:34 AM | theglobeandmail.comZura Bio Limited (NASDAQ:ZURA) Receives $10.75 Average PT from BrokeragesJune 8, 2026 | americanbankingnews.comHere's Why We're Not Too Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn SituationJune 3, 2026 | finance.yahoo.comZura Bio Announces Board Resignation, Governance Stability AffirmedMay 22, 2026 | tipranks.comAnalysts Are Bullish on These Healthcare Stocks: Silence Therapeutics (SLN), Zura Bio (ZURA)May 11, 2026 | theglobeandmail.comZura Bio Reports First Quarter 2026 Financial Results and Recent Corporate UpdatesMay 7, 2026 | businesswire.comZura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 4, 2026 | businesswire.comZura Bio Limited Class AApril 24, 2026 | edition.cnn.comOne Zura Bio Insider Raised Their Stake In The Previous YearApril 23, 2026 | finance.yahoo.comPiper Sandler Reaffirms Their Buy Rating on Zura Bio (ZURA)April 16, 2026 | theglobeandmail.comZura Bio: Momentum Is Real, But TibuSHIELD Needs To DeliverMarch 31, 2026 | seekingalpha.comZura Bio Reports Full Year 2025 Financial Results and Recent Corporate UpdatesMarch 19, 2026 | businesswire.comZura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World CongressMarch 5, 2026 | businesswire.comInsider Buying: Zura Bio (NASDAQ:ZURA) Major Shareholder Acquires 2,000,000 Shares of StockMarch 3, 2026 | insidertrades.comZura Bio to Participate in Upcoming Investor ConferencesMarch 2, 2026 | businesswire.comZura Bio Raises $144 Million To Advance Autoimmune Drug PipelineFebruary 27, 2026 | ventureburn.comVZura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesFebruary 27, 2026 | businesswire.comZura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded WarrantsFebruary 25, 2026 | businesswire.comZura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded WarrantsFebruary 24, 2026 | finance.yahoo.comZura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D.February 23, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLPTX, ZURA, GLSI, and LXEO Company DescriptionsGreenwich LifeSciences NASDAQ:GLSI$24.14 +0.73 (+3.12%) As of 12:49 PM Eastern This is a fair market value price provided by Massive. Learn more.Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.Leap Therapeutics NASDAQ:LPTXLeap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.Lexeo Therapeutics NASDAQ:LXEO$4.59 -0.06 (-1.29%) As of 12:55 PM Eastern This is a fair market value price provided by Massive. Learn more.Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.Zura Bio NASDAQ:ZURA$3.58 -0.11 (-2.85%) As of 12:55 PM Eastern This is a fair market value price provided by Massive. Learn more.Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Plot Twist: How the $110B Paramount-Warner Deal Rewrites Media Insiders Sell Top Tech Plays: Should Investors Buy, Sell, or Hold? What's Behind the Social Media Controversy Surrounding IonQ? This Golden Cross Could Send Urban Outfitters to New Highs Mission Control: Floating In SpaceX's Record-Breaking Orbit 3 Dividend Increases Investors Can Actually Trust RH’s Strong Q1 Still Leaves Investors With One Big Question SpaceX Rings the Bell and Shatters Every Record Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
